Viz.ai and UTMB Collaborate to Accelerate Recruitment in CHESS

May 31, 2024—Viz.ai and the University of Texas Medical Branch at Galveston (UTMB) recently announced a collaboration to incorporate Viz Subdural software into the CHESS study, which is collecting safety and efficacy data in patients with moderately symptomatic convexity chronic subdural hematoma (cSDH).

Peter Kan, MD, Professor and Chair of the Department of Neurosurgery at UTMB in Galveston, Texas, commented on the study and the collaboration in the press release.

“CHESS is designed to be the first United States randomized controlled trial to provide evidence on the safety and efficacy of standalone middle meningeal artery embolization versus surgical drainage using particle embolization,” stated Dr. Kan. “Viz.ai’s Subdural tool holds the promise of efficiently identifying prospective participants, thereby aiding in the timely completion of this important trial.”

As noted in the press release, the Viz Subdural algorithm was approved in 2022. The SDH-specific, artificial intelligence-powered detection and care coordination platform can identify suspected cases of acute and chronic subdural bleeds, then quickly notify the care team to review the patient case and make a treatment decision if necessary.

Viz Subdural is currently available commercially for triage and notification. Measuring SDH is not available for commercial use, advised the press release.

In the CHESS trial, Viz.ai will notify investigators immediately when it detects a patient who has suspected SDH and meets the eligibility criteria for enrollment. Study investigators can measure chronic bleeds and coordinate patient enrollment easily and securely through Viz.ai’s dynamic, mobile, Health Insurance Portability and Accountability Act–compliant platform. The study was funded by the National Institute of Neurological Disorders and Stroke, of the National Institutes of Health.